NRIX•benzinga•
Nurix Says FDA Granted Fast Track Designation For NX-5948 For Treatment Of Adult Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia After At Least Two Lines Of Therapy
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 19, 2024 by benzinga